Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5886035 | THEA PHARMA | Difluoroprostaglandin derivatives and their use |
Dec, 2017
(6 years ago) | |
US10864159 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(5 years from now) | |
US9999593 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(5 years from now) |
Zioptan is owned by Thea Pharma.
Zioptan contains Tafluprost.
Zioptan has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Zioptan are:
Zioptan was authorised for market use on 10 February, 2012.
Zioptan is available in solution/drops;ophthalmic dosage forms.
Zioptan can be used as reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Drug patent challenges can be filed against Zioptan from 11 February, 2016.
The generics of Zioptan are possible to be released after 28 May, 2029.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 10, 2017 |
Drugs and Companies using TAFLUPROST ingredient
NCE-1 date: 11 February, 2016
Market Authorisation Date: 10 February, 2012
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC